VanEck Associates
LKFT

VanEck Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

VanEck Associates’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65K Buy
2,153
+185
+9% +$6.13K ﹤0.01% 1325
2025
Q4 		$64K Buy
1,968
+750
+62% +$24.2K ﹤0.01% 1343
2025
Q3 		$42K Buy
1,218
+107
+10% +$3.42K ﹤0.01% 1349
2025
Q2 		$31K Hold
1,111
– – ﹤0.01% 1339
2025
Q1 		$28K Sell
1,111
-42
-4% -$1.06K ﹤0.01% 1324
2024
Q4 		$32K Buy
1,153
+400
+53% +$11.2K ﹤0.01% 1316
2024
Q3 		$23K Sell
753
-456
-38% -$12.4K ﹤0.01% 1308
2024
Q2 		$30K Hold
1,209
– – ﹤0.01% 1313
2024
Q1 		$39K Buy
1,209
+62
+5% +$2.31K ﹤0.01% 1290
2023
Q4 		$47K Buy
1,147
+191
+20% +$7.03K ﹤0.01% 1287
2023
Q3 		$33K Hold
956
– – ﹤0.01% 1311
2023
Q2 		$39K Hold
956
– – ﹤0.01% 1313
2023
Q1 		$37K Sell
956
-42
-4% -$1.73K ﹤0.01% 1325
2022
Q4 		$44K Buy
998
+230
+30% +$9.68K ﹤0.01% 1324
2022
Q3 		$33K Buy
+768
New +$39.4K ﹤0.01% 1292

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VanEck Associates's LKFT Position: Q1 2026 in Review

VanEck Associates increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 9.4% in Q1 2026, buying an estimated $6.13K and bringing the position to 2,153 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #1325.

VanEck Associates first reported a position in LKFT in Q3 2022 and has held it in 15 quarters since. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • VanEck Associates held 2,153 shares of Lakefront Biotherapeutics American Depositary Shares worth $65K as of Q1 2026.
  • VanEck Associates bought 185 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $6.13K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1325 holding.
  • VanEck Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and has held it in 15 quarters since.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.